🇺🇸 FDA
Patent

US 10342869

Compositions comprising anti-CD38 antibodies and lenalidomide

granted A61KA61K31/37A61K31/45

Quick answer

US patent 10342869 (Compositions comprising anti-CD38 antibodies and lenalidomide) held by The Regents of the University of California expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/37, A61K31/45, A61K31/454, A61K31/573